Vaccine effects and impact of vaccination programmes in post-licensure studies

Vaccine

Volumn 31, Issue 48, 2013, Pages 5634-5642

  Hanquet, Germaine ^a   Valenciano, Marta ^b   Simondon, François ^c   Moren, Alain ^b  

^a GHENT UNIVERSITY   (Belgium)

^b EPICONCEPT   (France)

^c Epidemiology Department at SPMSD   (France)

Author keywords

Epidemiology; Impact; Observational studies; Vaccination; Vaccine effectiveness

Indexed keywords

VACCINE;

HEALTH PROGRAM; HUMAN; LICENSING; MEDICAL PRACTICE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; VACCINATION; WORLD HEALTH ORGANIZATION;

EPIDEMIOLOGY; IMPACT; OBSERVATIONAL STUDIES; VACCINATION; VACCINE EFFECTIVENESS;

HUMANS; IMMUNIZATION PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES;

EID: 84886950595     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.006     Document Type: Review

References (67)

1. Note for guidance on the clinical evaluation of vaccines 2005 May, European Medicines Agency. Committee for human medicinal products (CHMP), EMA, CHMP, London.
2. Guidelines on clinical evaluation of vaccines: regulatory expectations 2004, World Health Organization.
3. Chen R.T., Orenstein W.A. Epidemiologic methods in immunization programs. Epidemiol Rev 1996, 18(January (2)):99-117.
4. Periodic benefit-risk evaluation report (PBRER) 2012, Committee for medicinal products for human use, European Medicines Agency, London.
5. Haber M., Longini I.M., Halloran M.E. Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol 1991, 20:300-310.
6. Vaccines and Biologicals Training manual on the critical regulatory function for vaccines: evaluation of clinical performance through authorized clinical trials. Prepared for national regulatory authorities of vaccine-procuring and vaccine-producing countries 2003, WHO, Word Health Organization, Geneva.
7. From the centers for disease control and prevention. Impact of vaccines universally recommended for children - United States, 1900-1998. JAMA 1999, 281(April (16)):1482-1483.
8. Centers for Disease Control and Prevention (CDC) Impact of vaccines universally recommended for children - United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999, 48(April (12)):243-248.
9. World Health Organization (WHO). Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. Geneva: WHO; 2008.
10. Halloran M.E., Haber M., Longini I.M., Struchiner C.J. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991, 133(February (4)):323-331.
11. Halloran M.E., Struchiner C.J. Study designs for dependent happenings. Epidemiology 1991, 2(5):331-338.
12. Centers for Disease Control and Prevention (CDC). Manual for the surveillance of vaccine-preventable diseases. 4th ed. Atlanta, GA; 2008.
13. Clemens J., Brenner R., Rao M., Tafari N., Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness?. JAMA 1996, 275(February (5)):390-397.
14. Tate J.E., Cortese M.M., Payne D.C., Curns A.T., Yen C., Esposito D.H., et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011, 30(January (Suppl. 1)):S56-S60.
15. Tate J.E., Panozzo C.A., Payne D.C., Patel M.M., Cortese M.M., Fowlkes A.L., et al. Decline and change in seasonality of us rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009, 124(August (2)):465-471.
16. Hanquet G., Ducoffre G., Vergison A., Neels P., Sabbe M., van Damme P., et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine 2011, 29(June (29/30)):4698-4703.
17. Hanquet G., Lernout T., Vergison A., Verhaegen J., Kissling E., Tuerlinckx D., et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 2011, 29(16):2856-2864.
18. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51(September (9)):717-722.
19. Enders P.J., Trepka M.J., Davis J.P. Impact of Haemophilus influenzae type b (Hib) conjugate vaccines on Haemophilus influenzae meningitis in Wisconsin. WMJ 2000, 99(August (5)):45-48.
20. Larrauri A., Cano R., Garcia M., Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23(July (32)):4097-4100.
21. Shim E., Galvani A.P. Distinguishing vaccine efficacy and effectiveness. Vaccine 2012, 30(47):6700-6705.
22. Broutin H., Mantilla-Beniers N.B., Simondon F., Aaby P., Grenfell B.T., Guegan J.F., et al. Epidemiological impact of vaccination on the dynamics of two childhood diseases in rural Senegal. Microbes Infect 2005, 7(April (4)):593-599.
23. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118(September (3)):865-873.
24. Cohen R., Levy C., de La Rocque F., Gelbert N., Wollner A., Fritzell B., et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25(11):1001-1007. [doi: 10.97/01.inf.0000243163.85163.a8].
25. Moore M.R., Hyde T.B., Hennessy T.W., Parks D.J., Reasonover A.L., Harker-Jones M., et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004, 190(December (11)):2031-2038.
26. Patel M.M., Parashar U.D. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009, 200(November (Suppl. 1)):S291-S299.
27. Rothmann K.J., Greenland S., Lash T.L. Modern epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia. 3rd ed.
28. Hanquet G., Moren A., Kissling E., Valenciano M Current challenges and new methodological approaches to assess vaccine effectiveness and vaccination impact. Conference report, September 28-30. Veyrier 2009.
29. Halloran M.E., Struchiner C.J., Longini I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997, 146(November (10)):789-803.
30. Gregg M.B. Field epidemiology 2008, Oxford University Press, Oxford. 3rd ed.
31. Spasoff R.A. Epidemiologic methods for health policy 1999, Oxford University Press, New York, Oxford.
32. Abramson J.H., Abramson Z.H. Making sense of data: a self-instruction manual on the interpretation of epidemiological data 2001, Oxford University Press, Oxford. 3rd ed.
33. Hennekens C.H., Buring J.E., Mayrent S.L. Epidemiology in medicine 1987, Little, Brown, Boston. 1st ed.
34. Porta M.S., Greenland S., Last J.M. A dictionary of epidemiology 2008, International Epidemiological Association, Oxford University Press, Oxford, New York. 5th ed.
35. Ruckinger S., van der Linden M., Reinert R.R., von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: an analysis using the indirect cohort method. Vaccine 2010, 28(July (31)):5012-5016.
36. Nichol K.L., Margolis K.L., Wuorenma J., von Sternberg T., The Efficacy Cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994, 331(12):778-784.
37. Jefferson T., Rivetti A., di Pietrantonj C., Demicheli V., Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012, 8:CD004879.
38. Esposito S., Lizioli A., Lastrico A., Begliatti E., Rognoni A., Tagliabue C., et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir Res 2007, 8:12.
39. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22(January (1)):10-16.
40. Prymula R., Hanovcova I., Splino M., Kriz P., Motlova J., Lebedova V., et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011, 29(February (10)):1959-1967.
41. Halloran M.E. Overview of vaccine field studies: types of effects and designs. J Biopharm Stat 2006, 16(4):415-427.
42. Halloran M.E., Longini I.M., Struchiner C.J. Design and interpretation of vaccine field studies. Epidemiol Rev 1999, 21(January (1)):73-88.
43. Rodrigues L.C., Smith P.G. Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev 1999, 21(January (1)):56-72.
44. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303(September (10)):549-552.
45. de Wals P., de Serres G Comments on the paper "the effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data" [P. Rivest, R. Allard, Vaccine 20 (2002) 2533-2536]. Vaccine 2003, 21(June (19/20)):2260-2261. [author reply 2].
46. Mahon B.E., Hsu K., Karumuri S., Kaplan S.L., Mason E.O., Pelton S.I., et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006, 24(March (14)):2514-2520.
47. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(October (10)):760-768.
48. de Serres G., Pilishvili T., Link-Gelles R., Reingold A., Gershman K., Petit S., et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012, 30(27):4067-4072.
49. Valenciano M., Kissling E., Ciancio B.C., Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010, 28(October (46)):7381-7388.
50. Castilla J., Beristain X., Martinez-Artola V., Navascues A., Garcia Cenoz M., Alvarez N., et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine 2010, 30(January (3)):539-543.
51. McCarthy N., Giesecke J. Case-case comparisons to study causation of common infectious diseases. Int J Epidemiol 1999, 28(August (4)):764-768.
52. Puig-Barbera J., Diez-Domingo J., Arnedo-Pena A., Ruiz-Garcia M., Perez-Vilar S., Mica-Esparza J.L. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine 2012, 30(39):5714-5720.
53. Cohen A.L., Taylor T., Farley M.M., Schaffner W., Lesher L.J., Gershman K.A., et al. An assessment of the screening method to evaluate vaccine effectiveness: the case of 7-valent pneumococcal conjugate vaccine in the United States. PLoS ONE 2012, 7(8):e41785.
54. Farrington C.P. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993, 22(August (4)):742-746.
55. Bonmarin I., Belchior E., le Strat Y., Levy-Bruhl D First estimates of influenza vaccine effectiveness among severe influenza cases, France, 2011/12. Euro Surveill 2012, 17(18). pii=20163.
56. Brown C., Lilford R. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006, 6(1):54.
57. Poehling K.A., Lafleur B.J., Szilagyi P.G., Edwards K.M., Mitchel E., Barth R., et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 2004, 114(September (3)):755-761.
58. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 16(September (36)):893-897. Centers for Disease Control and Prevention (CDC).
59. Gagneur A., Nowak E., Lemaitre T., Segura J-F., DelaperriÃ̈re Ng Abalea L., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine 2011, 29(21):3753-3759.
60. Greenwood M., Yule G.U. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med 1915, 8:113-194. [Sect Epidemiol State Med].
61. Patel M.M., Tate J., Cortese M., Payne D.C., Armstrong G., Parashar U.D., et al. The impact of indirect benefits of vaccination on postlicensure vaccine effectiveness estimates: a scenario analysis. Vaccine 2010, 28(November (50)):7987-7992.
62. Hanquet G., Perrocheau A., Kissling E., Bruhl D.L., Tarrago D., Stuart J., et al. Surveillance of invasive pneumococcal disease in 30EU countries: towards a European system?. Vaccine 2010, 28(May (23)):3920-3928.
63. Hanquet G., Kissling E., Fenoll A., George R., Lepoutre A., Lernout T., et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010, 16(September (9)):1428-1439.
64. Vesikari T., Karvonen A., Puustinen L., Zeng S-Q., Szakal E.D., Delem Ae, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004, 23(10):937-943.
65. Kissling E., Valenciano M., Falcao J., Larrauri A., Widgren K., Pitigoi D., et al. "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-2009. Euro Surveill 2009, 14(44). pii=19388.
66. Hviid A. Effectiveness of two pertussis vaccines in preterm Danish children. Vaccine 2009, 27(23):3035-3038.
67. Khan M.I., Soofi S.B., Ochiai R.L., Habib M.A., Sahito S.M., Nizami S.Q., et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012, 30(August (36)):5389-5395.